Journal of Clinical Densitometry
Volume 10, Issue 4 , Pages 376-380 , October 2007

Impact of HIV Infection on Total Body Composition in Treatment—Naive Men Evaluated by Dual-Energy X-ray Absorptiometry Comparison of 90 Untreated HIV-Infected Men to 241 Controls

  • C. Delpierre

      Affiliations

    • Unit of Infectious and Tropical Disease, Purpan Hospital, Toulouse, France
    • INSERM U558, Toulouse, France
    • IFR126, Toulouse, France
    • Corresponding Author InformationAddress correspondence to: C. Delpierre, PhD, Hôpital Purpan, Place du Docteur Baylac, 31059 Toulouse Cedex, Haute Garonne, France.
    • ,
  • E. Bonnet

      Affiliations

    • Unit of Infectious and Tropical Disease, Purpan Hospital, Toulouse, France
    • ,
  • F. Marion-Latard

      Affiliations

    • Unit of Sport Medicine, Rangueil Hospital, Toulouse, France
    • ,
  • C. Aquilina

      Affiliations

    • Unit of Dermatology, La Grave Hospital, Toulouse, France
    • ,
  • M. Obadia

      Affiliations

    • Unit of Infectious and Tropical Disease, Purpan Hospital, Toulouse, France
    • ,
  • B. Marchou

      Affiliations

    • Unit of Infectious and Tropical Disease, Purpan Hospital, Toulouse, France
    • ,
  • P. Massip

      Affiliations

    • Unit of Infectious and Tropical Disease, Purpan Hospital, Toulouse, France
    • ,
  • B. Perret

      Affiliations

    • Unit of Biochemistry, Purpan Hospital, Toulouse, France
    • ,
  • J. Bernard

      Affiliations

    • Unit of Rheumatology, Rangueil Hospital, Toulouse, France

Received 9 April 2007 ,Revised 26 July 2007 ,Accepted 27 July 2007.

References 

  1. Bonnet E, Delpierre C, Sommet A, et al. Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men. J Clin Densitom. 2005;8:287–292
  2. Cavalcanti R, Cheung A, Raboud J, Walmsley S. Reproducibility of DXA estimations of body fat in HIV lipodystrophy: implications for clinical research. J Clin Densitom. 2005;8:293–297
  3. Weinroth S, Parenti D, Simon G. Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches. Infect Agents Dis. 1995;4:76–94
  4. Cianfrocca M, Von Roenn J. Wasting and cachexia in patients with HIV. AIDS Patient Care STDs. 1997;11:259–267
  5. Carr A, Samaras K, Burton S. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:51–58
  6. Miller K, Jones E, Yanovski J, Shankar R, Feuerstein I, Falloon J. Visceral abdominal fat accumulation associated with use of indinavir. Lancet. 1998;351:871–875
  7. Saves M, Raffi F, Capeau J. Antiproteases cohorte (APROCO) study group: factors related to lipodystrophy and metabolic alterations in patients with human immuno-deficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002;34:1396–1405
  8. Mallal S, John M, Moore C, James I, McKinnon E. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients receiving long-term nucleoside analogue therapy. AIDS. 2000;14:1309–1316
  9. Carr A, Miller J, Law M, Cooper D. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:25–32
  10. Saint Marc T, Partisani M, Poizot-Martin I. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long term nucleoside analogue therapy. AIDS. 1999;13:1659–1667
  11. Garcia Aparicio A, Munoz Fernandez S, Gonzalez J, et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol. 2005;6:1–3
  12. Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res. 2004;19:402–409
  13. Bruera D, Luna N, David D, Bergoglio L, Zamudio J. Decreased bone mineral density in HIV-infected patients is dependent of antiretroviral therapy. AIDS. 2003;17:1917–1923
  14. Fausto A, Bongiovanni M, Cicconi P, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 2005;
  15. Thomas J, Doherty S. HIV infection—a risk factor for osteoporosis. J Acquir Immune Defic Syndr. 2003;33:281–291
  16. Miller J, Carr A, Smith D. Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS. 2000;14:2406–2407
  17. Martinez E, Mocroft A, Garcia-Viejo M. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592–598
  18. Madge S, Kinloch-de-Loes S, Mercey D, Johnson M, Weller I. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS. 1999;13:735–737
  19. Mazess R, Barden H, Drinka P, Bauwens S, Orwoll E, Bell N. Influence of age and body weight on spine and femur bone mineral density in US white men. J Bone Miner Res. 1990;5:645–652
  20. Charles M, Basdevant A, Eschwege E. Prevalence of obesity in France: the situation established from the OBEPI study. Ann Endocrinol. 2002;63:154–158
  21. Karlsson M, Gardsell P, Johnell O, Nilsson B, Akesson K, Obrant K. Bone mineral normative data in Malmo, Sweden. Comparison with reference data and hip fracture incidence in other ethnic groups. Acta Orthop Scand. 1993;64:168–172
  22. Jain R, Lenhard J. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem. 2002;277:247–250
  23. Seminari E, Castagna A, Soldarini A, et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med. 2005;6:145–150
  24. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48:39–48
  25. Das S, Shahmanesh M, Stolinski M, et al. In treatment naive and antiretroviral treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL, and LDL apolipoprotein B-100. Diabetologia. 2006;49:538–542
  26. Aukrust P, Haug C, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999;84:145–150
  27. Hansen A, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. HIV Med. 2006;7:38–45
  28. Lewis W, Kohler J, Hosseini S, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS. 2006;20:675–684
  29. Gerschenson M, Shiramizu B, LiButti D, Shikuma C. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir Ther. 2005;10:M83–M89
  30. Jones S, Qazi N, Morelese J, et al. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr. 2005;40:565–572

PII: S1094-6950(07)00199-0

doi: 10.1016/j.jocd.2007.07.006

Journal of Clinical Densitometry
Volume 10, Issue 4 , Pages 376-380 , October 2007

Article Tools